Passage Bio, a genetic medicines company developing AAV-delivered gene therapies, today announced a gene therapy development program for Charcot-Marie-Tooth Neuropathy Type 2A (CMT2A).
$1 Million Gift Pledged to CMT Type 2 Research!
Bob and Gail Buuck are big believers in “impact giving,” They have pledged a $1 million gift to advance CMT Type 2 research.
Type 1 CMT Gene Therapy Project Now Underway
CMTA and MDA Co-Fund Proof-of-Concept Study Using AAV Vector to
CMTA-Funded Research Database Identifies New Mutations
While researchers have identified more than 90 mutated genes that cause CMT, approximately 50 percent of CMT2 patients do not yet have a definitive genetic diagnosis. Dr. Stephan Züchner at the University of Miami is working to change that.
CMTA Announces $1 Million in Funding for STAR Research Projects
April 11, 2019 — The Charcot-Marie Tooth Association today announced
